Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals.
作者信息
Helwick Caroline
出版信息
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):36-9.
Abstract
摘要
相似文献
1
Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals.2015年多发性骨髓瘤的治疗飞跃：美国食品药品监督管理局前所未有的药物批准。
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):36-9.
2
Food and Drug Administration approvals in phase 3 Cancer clinical trials.食品和药物管理局批准的 3 期癌症临床试验。
BMC Cancer. 2021 Jun 12;21(1):695. doi: 10.1186/s12885-021-08457-5.
3
Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.通过开发已批准药物的新用途进行创新：补充适应症营销批准的趋势。
Clin Ther. 2013 Jun;35(6):808-18. doi: 10.1016/j.clinthera.2013.04.004. Epub 2013 May 28.
4
Approvals Expand Multiple Myeloma Treatment Options.批准扩大了多发性骨髓瘤的治疗选择。
Cancer Discov. 2021 Jun;11(6):OF5. doi: 10.1158/2159-8290.CD-NB2021-0338. Epub 2021 Apr 27.
5
Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.2017 年至 2019 年美国食品和药物管理局批准药品和生物制品补充适应症的临床研究特征。
JAMA Netw Open. 2021 Jun 1;4(6):e2113224. doi: 10.1001/jamanetworkopen.2021.13224.
6
An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).美国食品药品监督管理局（2006 - 2023年）药品批准中总生存期的实证分析。
Cancer Med. 2024 Apr;13(8):e7190. doi: 10.1002/cam4.7190.
7
An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed?2017-2021 年美国食品药品监督管理局批准的成人实体瘤药物评估：鹰是否已经着陆？
Nat Rev Clin Oncol. 2022 Jul;19(7):486-492. doi: 10.1038/s41571-022-00636-y. Epub 2022 Apr 28.
8
Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020.2014年至2020年FDA批准的PD-1/PD-L1抑制剂中生物标志物定义亚组的质量
Int J Cancer. 2022 Jun 1;150(11):1905-1910. doi: 10.1002/ijc.33968. Epub 2022 Feb 26.
9
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.微小残留病灶检测在多发性骨髓瘤治疗选择和药物研发中的作用：当前价值与未来应用。
Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.
10
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.程序性死亡配体 1（PD-L1）表达作为预测生物标志物的作用：对所有美国食品和药物管理局（FDA）批准的免疫检查点抑制剂的分析。
J Immunother Cancer. 2019 Oct 26;7(1):278. doi: 10.1186/s40425-019-0768-9.
引用本文的文献
1
Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma.识别欧洲血液学家和血液学护士在多发性骨髓瘤治疗与管理方面的教育需求和实践差距。
Hemasphere. 2018 Mar 1;2(2):e33. doi: 10.1097/HS9.0000000000000033. eCollection 2018 Mar-Apr.
本文引用的文献
1
Novel combination approaches for myeloma.骨髓瘤的新型联合治疗方法。
Hematology Am Soc Hematol Educ Program. 2015;2015:286-93. doi: 10.1182/asheducation-2015.1.286.
2
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.卡非佐米、来那度胺和地塞米松治疗复发多发性骨髓瘤。
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
3
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.帕比司他联合硼替佐米和地塞米松对比硼替佐米和地塞米松联合安慰剂治疗复发或复发难治性多发性骨髓瘤患者：一项多中心、随机、双盲的 3 期临床试验。
Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18.
4
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.来那度胺联合地塞米松治疗不适合移植的骨髓瘤患者。
N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.
Zotero 插件